Methotrexat Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing the production of tetrahydrofolate. This limits the synthesis of DNA, RNA and proteins, especially in rapidly dividing cells such as immune cells and cancer cells, thereby decreasing inflammation and tumor growth.

The exact dose of Methotrexat Accord is determined by the prescribing clinician based on the specific indication, patient weight, renal function and treatment goals. Healthcare providers calculate the appropriate regimen and adjust it according to clinical response and laboratory monitoring.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding; generally, the drug is avoided unless the benefits clearly outweigh potential risks to the infant.

To request Methotrexat Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexate is a folate antagonist, whereas other antimetabolites such as 5‑fluorouracil target thymidylate synthase. Methotrexate has a broader range of approved autoimmune and oncologic indications and is often used in lower‑dose weekly regimens for arthritis, while some alternatives may require continuous infusion or have different toxicity profiles.

Methotrexat Accord should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the product. If the product is supplied as a lyophilised powder, reconstitute according to the label instructions and use within the recommended time frame.

The medication is given by intra‑arterial, intramuscular or intravenous injection, depending on the clinical setting and indication. Administration is performed by qualified healthcare professionals under aseptic conditions, and dosing intervals are typically weekly for autoimmune diseases or as part of a chemotherapy protocol for cancer.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, acute renal failure and rare secondary malignancies. Patients should be monitored regularly with blood tests and clinical assessments to detect these complications early.

Methotrexat Accord is contraindicated in patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, and in pregnant women unless the potential benefit justifies the risk. It should also be avoided in individuals receiving live vaccines without appropriate medical supervision.